Asilomar Pharmaceuticals Overview
- Year Founded
-
1995
- Status
-
Acquired/Merged
- Latest Deal Type
-
Liquidation
Asilomar Pharmaceuticals General Information
Description
Developer of drugs to improve treatment of the central nervous system. The company has prototyped several anti-inflammatory agents to treat localized forms of neuropathic pain: Post-herpetic neuralgia, Trigeminal neuralgia, and Diabetic mononeuropathy.
Contact Information
Website
www.asilomarpharmaceuticals.comCorporate Office
- Suite 400, PMB 309
- New York, NY
- United States
Corporate Office
- Suite 400, PMB 309
- New York, NY
- United States
Asilomar Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Bankruptcy: Liquidation | 01-May-2007 | Completed | Bankruptcy: Liquidation | |||
| 1. Later Stage VC (Series A) | 01-Aug-2003 | Completed | Product Development |
Asilomar Pharmaceuticals Patents
Asilomar Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20040120891-A1 | B-l-m where b is an agent capable of selectively binding to a nerve cell surface receptor, mediating absorption by the nerve cell; m is a moiety which performs a useful non-cytotoxic function when absorbed by a nerve cell; and l is a linker | Inactive | 05-Sep-2002 | ||
| AU-2002243422-A1 | Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins | Inactive | 06-Nov-2000 | ||
| CA-2436830-A1 | Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins | Inactive | 06-Nov-2000 | ||
| EP-1349577-A2 | Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins | Inactive | 06-Nov-2000 | ||
| WO-2002047730-A2 | Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins | Inactive | 06-Nov-2000 | A61K47/6425 |
Asilomar Pharmaceuticals Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Asset Management Ventures | Venture Capital | Minority | ||
| Band of Angels | Angel Group | Minority | ||
| Lanfear Capital | Venture Capital | Minority | ||
| SBV Venture Partners | Venture Capital | Minority | ||
| Sears Capital Management | Venture Capital | Minority |
Asilomar Pharmaceuticals FAQs
-
When was Asilomar Pharmaceuticals founded?
Asilomar Pharmaceuticals was founded in 1995.
-
Where is Asilomar Pharmaceuticals headquartered?
Asilomar Pharmaceuticals is headquartered in New York, NY.
-
What industry is Asilomar Pharmaceuticals in?
Asilomar Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Asilomar Pharmaceuticals a private or public company?
Asilomar Pharmaceuticals is a Private company.
-
What is Asilomar Pharmaceuticals’s current revenue?
The current revenue for Asilomar Pharmaceuticals is .
-
How much funding has Asilomar Pharmaceuticals raised over time?
Asilomar Pharmaceuticals has raised $2.8M.
-
Who are Asilomar Pharmaceuticals’s investors?
Asset Management Ventures, Band of Angels, Lanfear Capital, SBV Venture Partners, and Sears Capital Management have invested in Asilomar Pharmaceuticals.
-
When was Asilomar Pharmaceuticals acquired?
Asilomar Pharmaceuticals was acquired on 01-May-2007.
-
Who acquired Asilomar Pharmaceuticals?
Asilomar Pharmaceuticals was acquired by Manzanita Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process